ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
6 hedge funds and large institutions have $3.95M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
14% less funds holding
Funds holding: 7 → 6 (-1)
44% less capital invested
Capital invested by funds: $7.04M → $3.95M (-$3.09M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
FNY Investment Advisers
New York
|
+$17.8K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.51K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$35K |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$26.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Temasek Holdings
Singapore
| $2.46M | – | – | – |
|
|
2
Baillie Gifford & Co
Edinburgh,
United Kingdom
| $724K | -$26.2K | -257 | -2% |
|
|
PIM
3
Platinum Investment Management
Sydney Australia 2000,
Australia
| $719K | – | – | – |
|
|
FIA
4
FNY Investment Advisers
New York
| $33K | +$17.8K | +175 | +58% |
|
|
5
UBS Group
Zurich,
Switzerland
| $7K | +$2.96K | +29 | +40% |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $3K | +$5.51K | +54 | New |
|
|
7
Millennium Management
New York
| – | -$35K | -288 | Closed |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$1K | -7 | Closed |
|
ASLN Hedge Fund Activity: Q3 2019 in Review
6 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q3 2019, worth a combined $3.95M — down 44% from $7.04M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ASLN and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was FNY Investment Advisers, adding an estimated $17.8K. The largest seller was Millennium Management, exiting entirely with an estimated $35K sold.
- 6 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q3 2019, down from 7 in Q2 2019.
- Funds reported $3.95M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q3 2019, down 44% quarter-over-quarter.
- 1 fund opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q3 2019 and 2 closed out, a net change of -1 holder.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q3 2019 was FNY Investment Advisers, an estimated $17.8K added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q3 2019 was Millennium Management, an estimated $35K sold.
Based on aggregated 13F filings for Q3 2019.